Ekaterina Belotserkovskaya

Mrs. Ekaterina Belotserkovskaya

Institute of Cytology RAS, 4 Tikhoretskii prospect, St. Petersburg, Russia 194064
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DBDaria Bogdanova
Daria Bogdanova
EKEkaterina Dmitrievna Kolosova
Ekaterina Dmitrievna Kolosova
TPTamara Pukhalskaia
Tamara Pukhalskaia
KLKsenia A. Levchuk
Ksenia A. Levchuk
Oleg DemidovOleg Demidov
Oleg Demidov
EBEkaterina Belotserkovskaya
Ekaterina Belotserkovskaya
The tumor microenvironment (TME) plays an essential role in tumor progression and in modulating tumor response to anticancer therapy. Cellular senescence leads to a switch in the cell secretome, characterized by the senescence-associated secretory phenotype (SASP), which may regulate tumorigenesis. Senolytic therapy is considered a novel anticancer strategy that eliminates the deleterious effects of senescent cells in the TME. Here, we show that two different types of senolytic drugs, despite efficiently depleting senescent cells, have opposite effects on cancer-associated fibroblasts (CAFs) and their ability to regulate epithelial–mesenchymal transition (EMT). We found that senolytic drugs, navitoclax and the combination of dasatinib/quercetin, reduced the number of spontaneously senescent and TNF-induced senescent CAFs. Despite the depletion of senescent cells, the combination of dasatinib/quercetin versus navitoclax increased the secretion of the SASP pro-inflammatory cytokine IL-6. This differential effect correlated with the promotion of enhanced migration and EMT in MC38 colorectal cancer cells. Our results demonstrate that some senolytics may have side effects unrelated to their senolytic activity and may promote tumorigenesis. We argue for more careful and extensive studies of the effects of senolytics on various aspects of tumor progression and tumor resistance to therapy before the senolytic strategy is implemented in the clinic.

19 September 2023 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
EBEkaterina Belotserkovskaya
Ekaterina Belotserkovskaya
VGVasily Golotin
Vasily Golotin
BUBurhan Uyanik
Burhan Uyanik
Oleg DemidovOleg Demidov
Oleg Demidov
Progress in the development of new sequencing techniques with wider accessibility and higher sensitivity of the protocol of deciphering genome particularities led to the discovery of a new phenomenon – clonal haematopoiesis. It is characterized by the presence in the bloodstream of elderly people a minor clonal population of cells with mutations in certain genes, but without any sign of disease related to the hematopoietic system. Here we will review this recent advancement in the field of clonal haematopoiesis and how it may affect the disease’s development in old age.

Verified
Journal Article
Open access
PDF file
EBEkaterina Belotserkovskaya
Ekaterina Belotserkovskaya
Oleg DemidovOleg Demidov
Oleg Demidov
Chronic myelomonocytic leukemia (CMML) is a rare and challenging type of myeloproliferative neoplasm. Poor prognosis and high mortality, associated predominantly with progression to secondary acute myeloid leukemia (sAML), is still an unsolved problem. Despite a growing body of knowledge about the molecular repertoire of this disease, at present, the prognostic significance of CMML-associated mutations is controversial. The absence of available CMML cell lines and the small number of patients with CMML make pre-clinical testing and clinical trials complicated. Currently, specific therapy for CMML has not been approved; most of the currently available therapeutic approaches are based on myelodysplastic syndrome (MDS) and other myeloproliferative neoplasm (MNP) studies. In this regard, the development of the robust CMML animal models is currently the focus of interest. This review describes important studies concerning animal models of CMML, examples of methodological approaches, and the obtained hematologic phenotypes.

12 November 2021 in Biological Communications
Verified
Journal Article
Closed access
PDF file
VGVasily Golotin
Vasily Golotin
EBEkaterina Belotserkovskaya
Ekaterina Belotserkovskaya
LGLarisa Girshova
Larisa Girshova
APAlexey Petukhov
Alexey Petukhov
AZAndrey Zaritsky
Andrey Zaritsky
Oleg DemidovOleg Demidov
Oleg Demidov
Recently wild-type p53-induced phosphatase was implicated in the pathogenesis of acute myeloid leukemia (AML) and “pre-leukemia” myeloproliferative conditions. Here we decided to check how the strategy directed to phosphatase inhibition affected sensitivity to conventional chemotherapy. All experiments were conducted on AML cell lines cultivated in vitro. The levels of wild-type p53-induced phosphatase vary in different AML cell lines. The chemical compound GSK2830371 reduced levels of phosphatase and diminished its activity. GSK2830371 did not significantly change the cell cycle distribution of AML cells when used alone or in combination with the anti-cancer chemotherapeutic drug Cytosar but increased caspase-dependent PARP1 cleavage. In contrast with previous studies, we did not observe the negative effect of phosphatase activity inhibition and depletion on cells when a chemical inhibitor was used as monotherapy. Using a combination of GSK2830371 with Cytosar we were able to reduce the threshold of chemotherapy-dependent cytotoxicity and more efficiently eliminate leukemic cells. We propose considering inhibition of wild-type p53-induced phosphatase as a prospective strategy in improving anti-AML therapy.

10 December 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
DSD. A. Senichkina
D. A. Senichkina
ASA. I. Shakirova
A. I. Shakirova
OEO. S. Epifanovskaya
O. S. Epifanovskaya
IGI. N. Gaponenko
I. N. Gaponenko
TPT. A. Pyatiizbyantsev
T. A. Pyatiizbyantsev
IMIvan Moiseev
Ivan Moiseev
Background. Myelodysplastic syndrome is a group of malignant blood diseases with a high risk of transformation into acute myeloid leukemia. One treatment approach is to target immune checkpoints (ICs) that are overexpressed on tumor cells. To develop these drugs, relevant models are needed for highthroughput screening and study of these biologically active substances, since traditionally used models (mouse and patient biomaterials) are difficult to access, financially and laborintensive, and are characterized by poorly reproducible results.Aim. To develop a model based on a human myeloid cell line with increased expression of L1 and TIM3 to study the activity of ICs inhibitors, the presence of which in the tumor microenvironment in patients with myelodysplastic syndrome and acute myeloid leukemia was associated with a high risk and worse prognosis.Materials and methods. Initial testing of the L1 and TIM3 basal expression level was carried out on cell lines: TH1, HL60, OCIAML2, OCIAML5, KG1, MonoMac1. Induction of IC expression was carried out using interferon γ. Analysis of marker expression was carried out 24 hours after induction of ICs expression and addition of MK2206 using flow cytometry.Results. Basal expression of the studied ICs receptors was absent in all of them, except for KG1; TIM3 was present in 88.4 ± 7.1 % of cells, and L1 – in 88 ± 8.5 %. The addition of interferon γ at a concentration of 50 ng/mL to the MonoMac1 culture led to a significant increase in the proportion of TIM3 and L1 expressing cells (53.3 ± 12.2 and 97.3 ± 1.1 % respectively, compared to 0.1 ± 0.1 and 0.1 ± 0.1 % without interferon γ), and for TH1 only L1 expression (87.5 ± 20 %, control 0.1 ± 0.1 %) was observed at the concentration of interferon γ in a medium of 50 ng/mL, while the proportion of cells expressing TIM3 was 6.9 ± 10 % (control 0.1 ± 0.1 %).Conclusion. The KG1 line, which constantly expresses significant levels of target ICs, as well as TH1 and MonoMac1, which are induced by 50 ng/mL interferon γ, were selected as a model with increased L1 and TIM3 expression based on a human myeloid cell line. The model efficiency was confirmed by the rational response to the IC pathway inhibitor.

7 April 2026 in Russian journal of hematology and transfusiology
Verified
Journal Article
Closed access
АSА. А. Shatilova
А. А. Shatilova
LGL. L. Girshova
L. L. Girshova
IBI. G. Budaeva
I. G. Budaeva
Oleg DemidovOleg Demidov
Oleg Demidov
EBEkaterina Belotserkovskaya
Ekaterina Belotserkovskaya
Introduction. Acute myeloid leukemia (AML) is characterized by a complex clonal structure formed as a result of clonal evolution. The study of clonal evolution is dictated by the need to improve the effectiveness of therapeutic strategies for AML. Aim: to review the current understanding of the clonal evolution of AML and analyze clonal evolution in real clinical practice using the example of three clinical cases. Main findings. A description of clinical cases with AML clonal evolution included 3 patients with newly diagnosed AML. Molecular genetic analysis of FLT3 and NPM1 genes was performed using commercial kits. The article reviews the main models of clonal evolution of AML: linear and parallel. The data from the study of leukemic stem cells are presented. Clonal evolution is demonstrated using the example of three clinical observations, explanations and recommendations for the selection of therapy are given. The clonal evolution of AML is a long and continuous process, which results in the formation of a complex branching pattern of molecular genetic breakdowns involving the leukemia stem cells. In this regard, at all stages of AML development (onset, remission, relapse), it is necessary to diagnose the maximum number of molecular genetic markers. Treatment taking into account knowledge of the patterns of clonal evolution is likely to improve the effectiveness of therapy.